Parenteral iron nephrotoxicity: potential mechanisms and consequences

Zager, Richard A.; Johnson, Ali C. M.; Hanson, Sherry Y.
July 2004
Kidney International;Jul2004, Vol. 66 Issue 1, p144
Academic Journal
journal article
Parenteral iron nephrotoxicity: Potential mechanisms and consequences. Background. Parenteral iron administration is a mainstay of anemia management in renal disease patients. However, concerns of potential iron toxicity persist. Thus, this study was conducted to more fully gauge iron toxicologic profiles and potential determinants thereof. Methods. Isolated mouse proximal tubule segments (PTS) or cultured proximal tubular [human kidney (HK-2)] cells were exposed to four representative iron preparations [iron sucrose (FeS), iron dextran (FeD), iron gluconate (FeG), or iron oligosaccharide (FeOS)] over a broad dosage range (0, 30 to 1000 μg iron/mL). Cell injury was assessed by lactate deyhdrogenase (LDH) release, adenosine triphosphate (ATP) reductions, cell cytochrome c efflux, and/or electron microscopy. In vivo toxicity (after 2 mg intravenous iron injections) was assessed by plasma/renal/cardiac lipid peroxidation [malondialdehyde (MDA)], renal ferritin (protein)/heme oxygenase-1 (HO-1) (mRNA) expression, electron microscopy, or postiron injection PTS susceptibility to attack. Results. In each test, iron evoked in vitro toxicity, but up to 30× differences in severity (e.g., ATP declines) were observed (FeS > FeG > FeD = FeOS). The in vitro differences paralleled degrees of cell (HK-2) iron uptake. In vivo correlates of iron toxicity included variable increases in renal MDA, ferritin, and HO-1 mRNA levels. Again, these changes appeared to parallel in vivo (glomerular) iron uptake (seen with FeS and FeG, but not with FeD or FeOS). Iron also effected in vivo alterations in proximal tubule cell homeostasis, as reflected by the “downstream” emergence of tubule resistance to in vitro oxidant attack. Conclusion. Parenteral iron formulations have potent, but highly variable, cytotoxic potentials which appear to parallel degrees of cell iron uptake (FeS > FeG ≫ FeD or FeOS). That in vitro injury can be expressed at clinically relevant iron concentrations, and that in vivo glomerular iron deposition/injury may result, suggest caution is warranted if these agents are to be administered to patients with active renal disease.


Related Articles

  • Toxicity of parenteral iron dextran therapy. Burns, David L.; Pomposelli, James J. // Kidney International Supplement;Mar1999, Issue 69, pS-119 

    Investigates the efficacy of parenteral iron dextran therapy on iron repletion in patients with iron-deficiency anemia. Toxicities associated with iron dextran use; Causes of iron deficiency; Mechanisms leading to iron dextran-induced symptoms.

  • Fatal anaphylactic reaction to iron sucrose in pregnancy. Mishra, Ajay; Dave, Nikhil; Viradiya, Kishor // Indian Journal of Pharmacology;Jan/Feb2013, Vol. 45 Issue 1, p93 

    Iron-deficiency anemia in pregnancy can have serious deleterious effects for both mother and fetus. Parenteral iron therapy in iron-deficiency anemia is recommended in patients where oral iron therapy is ineffective due to malabsorption states and noncompliance. Compared to oral iron therapy,...

  • Intravenous Iron Administration and Hypophosphatemia in Clinical Practice. Hardy, S.; Vandemergel, X. // International Journal of Rheumatology;4/27/2015, Vol. 2015, p1 

    Introduction. Parenteral iron formulations are frequently used to correct iron deficiency anemia (IDA) and iron deficiency (ID). Intravenous formulation efficacy on ferritin and hemoglobin level improvement is greater than that of oral formulations while they are associated with lower...

  • Contrast Media: Are There Differences in Nephrotoxicity among Contrast Media? Solomon, Richard // BioMed Research International;2014, Vol. 2014, p1 

    Iodinated contrast agents are usually classified based upon their osmolality-high, low, and isosmolar. Iodinated contrast agents are also nephrotoxic in some but not all patients resulting in loss of glomerular filtration rate. Over the past 30 years, nephrotoxicity has been linked to osmolality...

  • The Utility of Iron Chelators in the Management of Inflammatory Disorders. Lehmann, C.; Islam, S.; Jarosch, S.; Zhou, J.; Hoskin, D.; Greenshields, A.; Al-Banna, N.; Sharawy, N.; Sczcesniak, A.; Kelly, M.; Wafa, K.; Cheliak, W.; Holbein, B. // Mediators of Inflammation;3/23/2015, Vol. 2015, p1 

    Since iron can contribute to detrimental radical generating processes through the Fenton and Haber-Weiss reactions, it seems to be a reasonable approach to modulate iron-related pathways in inflammation. In the human organism a counterregulatory reduction in iron availability is observed during...

  • Iron and the endurance athlete1. Hinton, Pamela S. // Applied Physiology, Nutrition & Metabolism;Sep2014, Vol. 39 Issue 9, p1012 

    Iron is a trace mineral that is highly significant to endurance athletes. Iron is critical to optimal athletic performance because of its role in energy metabolism, oxygen transport, and acid-base balance. Endurance athletes are at increased risk for suboptimal iron status, with potential...

  • Introduction of Iron Transport by a Potent Inducer of Aryl Hydrocarbon Hydroxylase, 2, 3, 7, 8--Tetrachlorodibenzo-p-dioxin. Manis, James; Kim, Giho // Archives of Environmental Health;May/Jun79, Vol. 34 Issue 3 

    Examines the effectiveness of aryl hydrocarbon hydroxylase (AHH) 2,3,7,8-tetracholodibenzo-p-dioxin as an inducer of intestinal iron transport mechanism in rats. Oral and parenteral administration of the chemical; Impact of increased iron transport on AHH activity; Implication of the results...

  • Beyond efficacy and safety�the need for convenient and cost-effective iron therapy in health care. Bhandari, Sunil // NDT Plus;May2011, Vol. 4 Issue suppl_1, pi14 

    The National Service Framework advocates correction of anaemia in patients with chronic kidney disease (CKD). Oral iron is insufficient, while intravenous (IV) supplementation replenishes and maintains iron stores. Previously, effective delivery of iron therapy using available parenteral...

  • Optimal Management Strategies for Chronic Iron Overload. Barton, James C. // Drugs;2007, Vol. 67 Issue 5, p685 

    Iron overload is characterised by excessive iron deposition and consequent injury and dysfunction of target organs, especially the heart, liver, anterior pituitary, pancreas and joints. Iron overload disorders are common worldwide and occur in most major race/ethnicity groups. Physiological...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics